Zimmer Biomet Holdings Inc. ($ZBH) Stock Forecast: Down 2.1% Today

What is Zimmer Biomet Holdings Inc.?

Zimmer Biomet Holdings, Inc. (ZBH) is a prominent medical device company renowned for its orthopedic implants and surgical products. Their primary focus lies in creating cutting-edge solutions to enhance patient outcomes in musculoskeletal health.

Why is Zimmer Biomet Holdings Inc. going down?

ZBH stock is down 2.1% on May 11, 2026 14:55

• Today, ZBH's stock witnessed a notable downward trend for various reasons:
• Strong quarterly results and an improved earnings per share projection were overshadowed by ongoing investor concerns, resulting in a lack of trust among shareholders.
• The substantial sale of shares by Bryn Mawr Trust Advisors LLC likely contributed to the stock's decline, indicating a decrease in investor interest.
• Following the Chief Financial Officer's departure, the stock price dropped, leading to apprehensions about leadership stability and potential financial performance, influencing investor confidence.
• Despite ZBH's robust Q1 performance, the prevailing market view that the stock may be undervalued might have prompted profit-taking activities and selling pressure, prompting the bearish movement.

ZBH Price Chart

ZBH Technical Analysis

ZBH News

Augmented Bone Graft Market Is Going to Boom |• Medtronic • Stryker • Zimmer Biomet

Worldwide Market Reports has released a new study on the Augmented Bone Graft Market, providing an in-depth analysis of its size, forecast from 2026-2033, and key players like Medtronic, Stryker, and Zimmer Biomet. The report details competitive landscapes, market segments by type and application, and regional coverage. It aims to offer actionable insights to support strategic decision-making and investment planning in the sector.

https://www.openpr.com/news/4509369/augmented-bone-graft-market-is-going-to-boom-medtronic

Zimmer Biomet Earnings: Decent Quarterly Results Aren't Enough to Assuage Investor Worries

Zimmer Biomet reported decent first-quarter revenue of $2.09 billion, up 9.3% year over year, with organic growth at 3%. The operating margin improved by 260 basis points, and management raised its earnings per share outlook for 2026. Despite these positive indicators, the article suggests that these results were not enough to fully ease investor concerns.

https://www.morningstar.com/company-reports/1477378-zimmer-biomet-earnings-decent-quarterly-results-arent-enough-to-assuage-investor-worries?listing=0P0000061X

Bryn Mawr Trust Advisors LLC Sells 25,448 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Bryn Mawr Trust Advisors LLC reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 39% in the fourth quarter, selling 25,448 shares and retaining 39,824 shares worth $3.58 million. This comes as Zimmer Biomet reported strong quarterly results, with EPS and revenue exceeding analyst expectations. Despite varied analyst ratings, with an average "Hold" rating and a consensus price target of $102.80, the stock is currently trading near its 52-week low.

https://www.marketbeat.com/instant-alerts/filing-bryn-mawr-trust-advisors-llc-sells-25448-shares-of-zimmer-biomet-holdings-inc-zbh-2026-05-10/

Enovis Corporation (NYSE:ENOV) Q1 2026 Earnings Call Transcript

Enovis Corporation reported strong Q1 2026 earnings, surpassing expectations with an EPS of $0.89 against an anticipated $0.82. The company achieved 6% organic revenue growth on a days-adjusted basis, driven by 8% growth in Recon and 3% in Prevention & Recovery. Key drivers included the successful launch and adoption of the Arvis augmented reality system in Recon and continued market share gains in both segments despite a dynamic macroeconomic environment.

https://www.insidermonkey.com/blog/enovis-corporation-nyseenov-q1-2026-earnings-call-transcript-1757977/

A Look At Zimmer Biomet (ZBH) Valuation After Strong Q1 2026 Results And CFO Transition

Zimmer Biomet (ZBH) reported strong Q1 2026 results with increased sales and net income, alongside reaffirming full-year revenue guidance. The company also announced the departure of CFO Suketu Upadhyay and appointed an interim successor. Despite these positive updates, the stock has seen a recent decline, prompting investors to consider if it is undervalued, with one narrative suggesting it is 19% undervalued based on a $103 fair value estimate.

https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/a-look-at-zimmer-biomet-zbh-valuation-after-strong-q1-2026-r

Trending Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

Five Below Inc. ($FIVE) Stock Forecast: Down 5.4% Today

Whirlpool Corporation ($WHR) Stock Forecast: Down 5.3% Today

Excelerate Energy ($EE) Stock Forecast: Up 5.0% Today

Novavax Inc. ($NVAX) Stock Forecast: Down 5.6% Today

PVH Corp. ($PVH) Stock Forecast: Down 5.1% Today

Wix.com Ltd. ($WIX) Stock Forecast: Down 5.3% Today

Tesla Inc. ($TSLA) Stock Forecast: Up 3.4% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 5.5% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Up 5.5% Today

Zimmer Biomet Holdings Inc. Price History

13.00.2026 - ZBH Stock was down 2.3%

• During the third quarter of 2025, Nisa Investment Advisors LLC notably decreased its ownership in Zimmer Biomet Holdings, Inc. by 39.8%, potentially indicating a lack of faith in the company's upcoming performance, which might have contributed to the recent market decline.
• Zimmer Biomet Holdings Inc. demonstrated weaker performance compared to its industry counterparts, potentially due to factors beyond what has been publicly revealed, fostering a pessimistic market mood.
• The departure of Mark Bezjak, a vital executive at Zimmer Biomet Holdings, triggered concerns among shareholders regarding leadership stability and future strategic plans, adversely affecting the stock value.
• Following Mark R. Bezjak's appointment at Dentsply Sirona, where he previously held leadership positions at Zimmer Biomet, investors may have grown uneasy about potential competitive shifts towards a rival firm, leading to the downturn in Zimmer Biomet's stock price.

11.04.2026 - ZBH Stock was down 2.1%

• Today, ZBH's stock witnessed a notable downward trend for various reasons:
• Strong quarterly results and an improved earnings per share projection were overshadowed by ongoing investor concerns, resulting in a lack of trust among shareholders.
• The substantial sale of shares by Bryn Mawr Trust Advisors LLC likely contributed to the stock's decline, indicating a decrease in investor interest.
• Following the Chief Financial Officer's departure, the stock price dropped, leading to apprehensions about leadership stability and potential financial performance, influencing investor confidence.
• Despite ZBH's robust Q1 performance, the prevailing market view that the stock may be undervalued might have prompted profit-taking activities and selling pressure, prompting the bearish movement.

10.01.2026 - ZBH Stock was up 5.3%

• Strong fourth-quarter financial results from Zimmer Biomet exceeded revenue and earnings predictions, leading to the stock's upward trend.
• Despite the positive results, the company's cautious approach to its 2026 guidance, citing the ever-changing healthcare landscape, initially caused a slight decline in pre-market stock prices.
• The strategic shift towards a direct and specialized sales model in the U.S., as highlighted by the CEO, likely bolstered investor confidence in the company's future growth.
• A newly announced $1.5 billion stock repurchase program also contributed to positive investor sentiment and the stock's upward trajectory.

29.03.2026 - ZBH Stock was down 6.8%

• Despite reporting strong Q1 2026 results and surpassing earnings expectations, Zimmer Biomet Holdings experienced a bearish trend, likely driven by investors taking profits following a period of positive performance.
• Activities of various analysts, including adjustments in price targets and ratings by JPMorgan and Goldman Sachs, might have impacted market sentiment and contributed to the bearish movement.
• The resignation of CFO Suky Upadhyay may have sparked concerns among investors regarding potential internal changes or challenges within the company, leading to a negative impact on the stock price.
• The broader market sentiment towards medical device companies, exemplified by Mitsubishi UFJ Trust & Banking Corp reducing its stake in Edwards Lifesciences Corporation, could have also played a role in influencing the stock performance of ZBH.

14.00.2026 - ZBH Stock was down 5.2%

• ZBH shares exhibited a significant drop following the company's conservative statements about its future at the J.P. Morgan Healthcare Conference, reflecting concerns among investors about its upcoming performance.
• Despite the recent bearish market movement, evaluations still consider Zimmer Biomet a worthwhile investment opportunity, supported by favorable valuation metrics and financial stability. This indicates that short-term apprehensions may be overshadowing its long-term prospects.
• The decision from Nisa Investment Advisors LLC to sell ZBH shares, alongside other institutional investors increasing their holdings, could have amplified the selling pressure, contributing to the downward trend.
• The recent appointment of Mark R. Bezjak as Group Vice President at Dentsply Sirona, who had a prior role at Zimmer Biomet, might have indirectly influenced the market sentiment towards ZBH, prompting investors to evaluate potential implications on competitiveness and industry dynamics.

04.01.2026 - ZBH Stock was up 2.8%

• ZBH stock experienced a strong bullish movement recently.
• Positive market sentiment was fueled by expectations of increased earnings and higher revenues for the quarter ending December 2025.
• Despite some analyst revisions and a negative Earnings ESP, optimistic growth projections and the company's robust fundamentals likely boosted investor confidence.
• The increase in stake by the National Pension Service and the company's solid reputation as a reliable dividend cornerstone might have positively impacted the stock's performance.

28.03.2026 - ZBH Stock was down 7.7%

• Experienced a strong bearish movement today.
• The departure of the Chief Financial Officer, Suketu Upadhyay, and the appointment of an interim CFO may have caused uncertainty and investor concern.
• The market reacted negatively to the CFO transition, possibly interpreting it as a potential disruption to Zimmer Biomet's growth and margin initiatives.
• Investors may be monitoring the situation closely for any further developments or announcements regarding the company's financial leadership.

28.03.2026 - ZBH Stock was down 10.1%

• Zimmer Biomet Holdings Inc. is a medical device company that focuses on designing, manufacturing, and marketing orthopedic reconstructive products. The company operates globally, with a strong presence in the medical technology market.
• Recently, ZBH stock dropped by about 6% due to various factors.
• The departure of the CFO and the company's reaffirmation of its full-year revenue outlook in the Q1 report led to the largest single-day decline in the stock since November.
• Investor sentiment may have been impacted by uncertainty regarding leadership changes and their potential effects on financial performance.
• Investors are closely following Zimmer Biomet's growth and margin strategies, particularly in the medical technology sector, amidst ongoing changes in top leadership roles.

28.03.2026 - ZBH Stock was down 6.7%

• Following the departure of the CFO, Suketu Upadhyay, despite the positive financial outcomes and upgraded full-year guidance, investor uncertainty emerged, triggering a downward trend in the stock price.
• The market's response to the appointment of an interim CFO and the impending search for a permanent successor is viewed as a potential risk factor to the company's future financial performance.
• The prevailing bearish momentum might also be influenced by profit-taking actions subsequent to the strong earnings disclosure, prompting investors to review the stock's valuation and growth prospects in the medical technology sector.

14.03.2026 - ZBH Stock was up 5.3%

• The bullish movement in ZBH stock can be attributed to positive analyst coverage and market sentiment surrounding the company's resilience in navigating supply chain challenges in the medtech industry.
• Analysts' cautiously optimistic views, particularly from Leerink Partners initiating coverage with a Market Perform rating and a price target of $101.00, have likely bolstered investor confidence in Zimmer Biomet's long-term growth prospects.
• The company's recent surpassing of Q4 earnings expectations and strategic restructuring, including the launch of new products like the mBôs robot, have also contributed to the positive momentum in its stock price.
• Despite potential near-term growth limitations due to market dynamics, ZBH's strong balance sheet, leadership in robotics, and focus on addressing supply chain disruptions position it favorably for sustained gains in the future.

05.10.2025 - ZBH Stock was down 12.5%

• Weak performance in Latin America and specific EU markets affected the projected organic growth, resulting in a decline in the stock value.
• Despite the positive earnings, the stock has been on a downward trajectory in the past year, potentially contributing to the recent bearish trend.
• An uptick in short interest as a percentage of float suggests a growing bearish outlook among investors, adding to the downward pressure on the stock.
• Market sentiment towards Zimmer Biomet Holdings Inc. appears cautious, with investors closely monitoring its performance in key markets.

05.10.2025 - ZBH Stock was down 15.5%

• Despite Zimmer Biomet exceeding Q3 earnings forecasts, the stock faced a decline in revenue and a reduced outlook, resulting in an early slide.
• Challenges in Latin America and select EU markets affected the company's projected organic growth, contributing to the stock's downward trend.
• The stock price dropped by 0.84% in the latest market session, marking a significant 9.34% decrease over the past year.
• Zimmer Biomet Holdings Inc.'s short interest as a percentage of float has increased, indicating a rise in bearish sentiment among investors.